Research & Development Overview

Fixx Pharmaceuticals research and development resources are devoted to identifying next-generation therapies for Hemophilia and other inherited bleeding disorders.  

What We Hope To Achieve

In Q4 of 2021, Fixx hopes to begin its first clinical trial to investigate the effectiveness of gene editing by using custom-matched zinc finger nucleases.  (ZFNs)


By using ZFNs specific for the factor 8 and Factor 9 genes in conjunction with its DNA sequence, Fixx hopes to restore normal gene function in hemophilia patients.